www.gandul.ro/international/stiinta/vaccin-experim

Recent research indicates that an experimental vaccine, camupepimut, has successfully activated the immune system in nearly all evaluated pancreatic cancer patients. This vaccine targets KRAS mutations, common in pancreatic tumors, aiming to help the immune system recognize and attack cancer cells. While 98.9% of vaccinated patients developed a T-cell response, the study did not show a significant difference in recurrence-free survival compared to the control group. The findings suggest potential for immunotherapy in pancreatic cancer treatment, but further studies are needed to assess long-term survival benefits and the effectiveness of booster doses or combination therapies.